News

Under the deal, Kinex will receive an upfront payment, milestones and royalties, while PharmaEssentia has committed to carryout clinical studies in Taiwan to contribute to the global registration

DavosPharma is expected to complete the manufacturing of the drug in the second quarter of 2014 and is also in the process of preparing its investigational new drug

XLMTM is a rare, inherited disorder characterized by severe muscle weakness and respiratory impairment. The company said that AT001 is a novel drug candidate based on adeno-associated virus

The new facility will offer manufacturing capacity for emerging compounds within the company’s oncology and immunology pipeline to serve markets globally. Scheduled to be operational by 2019, the

US patent No. 8,642,564 provides methods for oral delivery of nucleotide-oligomer analogs including anti-sense and RNA interference drugs. Such drugs represent an important new class of therapeutics but

This patent provides for once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5a-reductase to patients with nodulocystic and conglobate acne vulgaris.

Under the deal, the company will have sole rights to develop and market the technology across the world. The company said that protecting the fundamental enabling technology establishes

The trials will be conducted under the supervision of GRU Cancer Center director and former chief of the Vaccines Section at the National Cancer Institute Dr Samir Khleif.

For the acquisition, Innate Pharma will pay €2m in cash and 600,000 shares to Novo Nordisk for licencing the anti-NKG2A antibody. In addition, Novo Nordisk may be eligible